HALO logo

Halozyme Therapeutics (HALO) Long Term Liabilities

HALO Annual Total Long Term Liabilities

$1.54 B
-$3.96 M-0.26%

31 December 2023

HALO Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

HALO Quarterly Long Term Liabilities

$1.56 B
+$9.84 M+0.64%

30 September 2024

HALO Quarterly Long Term Liabilities Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

HALO Long Term Liabilities Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-0.3%+1.9%
3 y3 years+10000.0%+1.9%
5 y5 years+3559.4%+1.9%

HALO Long Term Liabilities High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-0.3%+94.5%-6.1%+97.0%
5 y5-year-0.3%>+9999.0%-6.1%>+9999.0%
alltimeall time-0.3%-6.1%

Halozyme Therapeutics Long Term Liabilities History

DateAnnualQuarterly
Sept 2024
-
$1.56 B(+0.6%)
June 2024
-
$1.55 B(+1.0%)
Mar 2024
-
$1.53 B(-0.3%)
Dec 2023
$1.54 B(-0.3%)
$1.54 B(+0.6%)
Sept 2023
-
$1.53 B(-1.0%)
June 2023
-
$1.54 B(+0.1%)
Mar 2023
-
$1.54 B(+0.0%)
Dec 2022
$1.54 B(+95.0%)
$1.54 B(-7.1%)
Sept 2022
-
$1.66 B(+28.7%)
June 2022
-
$1.29 B(+63.1%)
Mar 2022
-
$790.30 M(-0.0%)
Dec 2021
$790.33 M(>+9900.0%)
$790.33 M(-0.0%)
Sept 2021
-
$790.59 M(-0.2%)
June 2021
-
$791.86 M(+0.0%)
Mar 2021
-
$791.57 M(>+9900.0%)
Dec 2020
$7.49 M(-98.1%)
$7.49 M(-98.1%)
Sept 2020
-
$398.06 M(+0.7%)
June 2020
-
$395.35 M(+0.8%)
Mar 2020
-
$392.31 M(+1.0%)
Dec 2019
$388.47 M(+824.9%)
$388.47 M(+2190.2%)
Sept 2019
-
$16.96 M(-24.1%)
June 2019
-
$22.36 M(-26.4%)
Mar 2019
-
$30.40 M(-27.6%)
Dec 2018
$42.00 M(-76.7%)
$42.00 M(-36.0%)
Sept 2018
-
$65.65 M(-24.9%)
June 2018
-
$87.40 M(-21.4%)
Mar 2018
-
$111.18 M(-38.3%)
Dec 2017
$180.25 M(-24.7%)
$180.25 M(-1.3%)
Sept 2017
-
$182.71 M(-10.4%)
June 2017
-
$204.01 M(-8.7%)
Mar 2017
-
$223.56 M(-6.6%)
Dec 2016
$239.41 M(+213.6%)
$239.41 M(-1.0%)
Sept 2016
-
$241.83 M(-2.2%)
June 2016
-
$247.32 M(+14.8%)
Mar 2016
-
$215.40 M(+182.2%)
Dec 2015
$76.33 M(-23.9%)
$76.33 M(-7.0%)
Sept 2015
-
$82.08 M(-7.5%)
June 2015
-
$88.78 M(-6.9%)
Mar 2015
-
$95.37 M(-4.9%)
Dec 2014
$100.29 M
$100.29 M(+11.3%)
DateAnnualQuarterly
Sept 2014
-
$90.09 M(-5.2%)
June 2014
-
$95.03 M(+0.5%)
Mar 2014
-
$94.58 M(-2.4%)
Dec 2013
$96.88 M(+44.8%)
$96.88 M(+30.9%)
Sept 2013
-
$74.01 M(+16.7%)
June 2013
-
$63.41 M(-3.1%)
Mar 2013
-
$65.43 M(-2.2%)
Dec 2012
$66.93 M(+78.2%)
$66.93 M(+87.2%)
Sept 2012
-
$35.75 M(-1.7%)
June 2012
-
$36.37 M(-1.7%)
Mar 2012
-
$36.98 M(-1.5%)
Dec 2011
$37.56 M(-32.5%)
$37.56 M(+0.4%)
Sept 2011
-
$37.40 M(-1.4%)
June 2011
-
$37.91 M(-30.8%)
Mar 2011
-
$54.81 M(-1.5%)
Dec 2010
$55.65 M(-0.4%)
$55.65 M(+3.8%)
Sept 2010
-
$53.61 M(-1.7%)
June 2010
-
$54.54 M(-0.1%)
Mar 2010
-
$54.59 M(-2.2%)
Dec 2009
$55.85 M(+18.9%)
$55.85 M(+4.0%)
Sept 2009
-
$53.70 M(-1.8%)
June 2009
-
$54.69 M(+5.8%)
Mar 2009
-
$51.67 M(+10.0%)
Dec 2008
$46.96 M(+27.5%)
$46.96 M(+21.0%)
Sept 2008
-
$38.80 M(-1.7%)
June 2008
-
$39.49 M(-1.3%)
Mar 2008
-
$40.00 M(+8.6%)
Dec 2007
$36.83 M(+96.3%)
$36.83 M(+0.0%)
Sept 2007
-
$36.82 M(+34.5%)
June 2007
-
$27.37 M(-1.6%)
Mar 2007
-
$27.81 M(+48.2%)
Dec 2006
$18.76 M(>+9900.0%)
$18.76 M(>+9900.0%)
Mar 2004
-
$0.00(0.0%)
Sept 2003
-
$0.00(0.0%)
June 2003
-
$0.00(0.0%)
Mar 2003
-
$0.00(0.0%)
Sept 2002
-
$0.00(0.0%)
June 2002
-
$0.00(0.0%)
Mar 2002
-
$0.00
Dec 2001
$0.00
-

FAQ

  • What is Halozyme Therapeutics annual total long term liabilities?
  • What is the all time high annual total long term liabilities for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual total long term liabilities year-on-year change?
  • What is Halozyme Therapeutics quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?

What is Halozyme Therapeutics annual total long term liabilities?

The current annual total long term liabilities of HALO is $1.54 B

What is the all time high annual total long term liabilities for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual total long term liabilities is $1.54 B

What is Halozyme Therapeutics annual total long term liabilities year-on-year change?

Over the past year, HALO annual total long term liabilities has changed by -$3.96 M (-0.26%)

What is Halozyme Therapeutics quarterly total long term liabilities?

The current quarterly long term liabilities of HALO is $1.56 B

What is the all time high quarterly long term liabilities for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly total long term liabilities is $1.66 B

What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?

Over the past year, HALO quarterly total long term liabilities has changed by +$28.22 M (+1.85%)